ライフサイエンスコーパス: Roux-en-Y gastric bypass

1 , and a combination of both methods, such as Roux-en-Y gastric bypass.

2 adjustable gastric banding and laparoscopic Roux-en-Y gastric bypass.

3 from the changes seen in weight loss without Roux-en-Y gastric bypass.

4 col and 60 were randomly assigned to undergo Roux-en-Y gastric bypass.

5 the duodenal-jejunal bypass component of the Roux-en-Y gastric bypass.

6 ared to the laparoscopic gastric band or the Roux-en-Y gastric bypass.

7 r reduced drug bioavailability 1 month after Roux-en-Y gastric bypass.

8 ll and complication rates after laparoscopic Roux-en-Y gastric bypass.

9 The most commonly performed operation is Roux-en-Y gastric bypass.

10 operations, the majority being laparoscopic Roux-en-Y gastric bypass.

11 Laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass.

12 roscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass.

13 eta-cell mass expansion to explain PBH after Roux-en-Y gastric bypass.

14 abetes, hypertension, and dyslipidemia after Roux-en-Y gastric bypass.

15 e treatment and of adult controls undergoing Roux-en-Y gastric bypass.

16 scopic adjustable gastric banding to 76% for Roux-en-Y gastric bypass.

17 Patients undergoing Roux-en-Y gastric bypass (161 participants) or sleeve ga

18 the most common BS type (65.7%) followed by Roux-en-Y gastric bypass (27.6%) and gastric banding (4.

19 The BS procedures included 20 Roux-en-Y gastric bypass (61%), 6 jejunoileal bypass (18

20 rdized procedure for mouse and rat models of Roux-en-Y gastric bypass (80-90 min operative time) and

21 he most widely performed surgical procedure, Roux-en-Y gastric bypass, achieves permanent (followed u

22 ve demonstrated the overall effectiveness of Roux-en-Y gastric bypass, adjustable gastric banding, an

23 height in meters squared], >35) eligible for Roux-en-Y gastric bypass, aged between 35 and 55 years,

24 , 42-51]; 78% women): 1513 who had undergone Roux-en-Y gastric bypass and 509 who had undergone lapar

25 or BMI >35 with comorbidities) eligible for Roux-en-Y gastric bypass and aged 35 to 55 years were en

26 Roux-en-Y gastric bypass and biliopancreatic diversion c

27 conventional bariatric operations-especially Roux-en-Y gastric bypass and laparoscopic adjustable gas

28 ost commonly performed bariatric procedures, Roux-en-Y gastric bypass and laparoscopic adjustable gas

29 Roux-en-Y gastric bypass and SG are associated with comp

30 e the association between metabolic surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) and maj

31 Bariatric surgery (n = 5053), including Roux-en-Y gastric bypass and sleeve gastrectomy, vs nons

32 Weight loss surgery including Roux-en-Y gastric bypass and sleeve gastrectomy.

33 ion by restricting gastric size; in addition Roux-en-Y gastric bypass and to a lesser extent sleeve g

34 in patients who have undergone laparoscopic Roux-en-Y gastric bypass and to develop decision tree mo

35 Surgery (Roux-en-Y gastric bypass and vertical sleeve gastrectomy

36 Bariatric surgeries, such as Roux-en-Y gastric bypass and vertical sleeve gastrectomy

37 nderstanding of the microbiome changes after Roux-en-Y gastric bypass and weight loss; and (3) a basi

38 t of Bariatric Surgery (85 women underwent a Roux-en-Y gastric bypass, and 21 women underwent laparos

39 t loss of 10% to 20% for sleeve gastrectomy, Roux-en-Y gastric bypass, and one anastomosis gastric by

40 ato-biliary tree in those who have undergone Roux-en-Y gastric bypass, and relieving pancreato-biliar

41 the safety and efficacy of the laparoscopic Roux-en-Y gastric bypass, and several papers address the

42 es with the excluded biliopancreatic limb in Roux-en-Y gastric bypass, and this may provide a novel e

43 de cholangiopancreatography in patients with Roux-en-Y gastric bypass are discussed.

44 Although vertical banded gastroplasty and Roux-en-Y gastric bypass are the two procedures most com

45 13-18 years) with severe obesity undergoing Roux-en-Y gastric bypass at three specialised paediatric

46 hrelin were reduced after VSG, but not after Roux-en-Y gastric bypass, based on enzyme-linked immunos

47 underwent laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass between January 1, 2012, to Dec

48 bariatric surgery were offered laparoscopic Roux-en-Y gastric bypass between July 1997 and March 200

49 Roux-en-Y gastric bypass can be successfully performed i

50 nt (gastric banding, sleeve gastrectomy, and Roux-en Y gastric bypass) can produce remarkable health

51 Roux-en-Y gastric bypass causes increased secretion of g

52 uding bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass), colorectal surgery (colectomy

53 Bile diversion in preclinical Roux-en-Y gastric bypass confers its antitumor effects i

54 trectomy, one anastomosis gastric bypass, or Roux-en-Y gastric bypass (confirmed with barium swallow

55 Approximately 11 % of patients who underwent Roux-en-Y gastric bypass develop symptomatic gallstone d

56 t of young people aged 13-21 years underwent Roux-en-Y gastric bypass for clinically severe obesity a

57 cal Data Base for all patients who underwent Roux-en-Y gastric bypass for the treatment of morbid obe

58 Laparoscopic Roux-en-Y gastric bypass for weight loss is being perfor

59 database who underwent sleeve gastrectomy or Roux-en-Y gastric bypass from 2012 to 2017.

60 Roux-en-Y gastric bypass (GB) and sleeve gastrectomy (SG

61 Rerouted gut after Roux-en-Y gastric bypass (GB) and, to a lesser degree, a

62 f the endocrine system in patients following Roux-en-Y gastric bypass (GBP) are poorly described and

63 In all years, laparoscopic Roux-en-Y gastric bypass generated the highest number of

64 ary endpoint was significantly higher in the Roux-en-Y gastric bypass group (54 [56%]) and sleeve gas

65 greater (95% CI 2.19-5.92; p<0.0001) in the Roux-en-Y gastric bypass group and 3.67 times greater (2

66 as met in 54 (70%) of 77 participants in the Roux-en-Y gastric bypass group and 55 (70%) of 79 partic

67 : Adolescents with severe obesity undergoing Roux-en-Y gastric bypass had substantial weight loss ove

68 Roux-en-Y gastric bypass has a higher complication rate

69 h the ideal procedure has yet to be devised, Roux-en-Y gastric bypass has proved to be successful for

70 ggested that in people with type 2 diabetes, Roux-en-Y gastric bypass has therapeutic effects on meta

71 showed that both procedures were safe, with Roux-en-Y gastric bypass having higher weight loss and f

72 %) in 3-year percent weight change following Roux-en-Y gastric bypass, ie, weekly self-weighing, cont

73 Roux-en-Y gastric bypass improves glycemic control in pa

74 eratively, 6 months, and 1 and 5 years after Roux-en-Y gastric bypass in 102 patients.

75 The authors attempted total laparoscopic Roux-en-Y gastric bypass in 281 consecutive patients.

76 We evaluated the health effects of Roux-en-Y gastric bypass in a cohort of adolescents (161

77 to analyse long-term (>5 years) outcomes of Roux-en-Y gastric bypass in a cohort of young adults who

78 ential predictor of diabetes remission after Roux-en-Y gastric bypass in obesity.

79 The improvement in beta-cell function after Roux-en-Y gastric bypass in patients with type 2 diabete

80 nd February, 2007, 74 young people underwent Roux-en-Y gastric bypass in the FABS study.

81 oscopic sleeve gastrectomy with laparoscopic Roux-en-Y gastric bypass in the treatment of severe obes

82 We performed Roux-en-Y gastric bypass in two morbidly obese patients

83 treated adolescents and of adults undergoing Roux-en-Y gastric bypass, in the Adolescent Morbid Obesi

84 Complications after Roux-en-Y gastric bypass include anastomotic leaks and s

85 Roux-en-Y gastric bypass induced significantly greater w

86 The Roux-en-Y gastric bypass is a highly successful approach

87 Laparoscopic Roux-en-Y gastric bypass is a new and technically challe

88 Although weight loss following Roux-en-Y gastric bypass is acceptable in patients with

89 Laparoscopic Roux-en-Y gastric bypass is effective in achieving weigh

90 ing from microbial sequencing analyses after Roux-en-Y gastric bypass is the comparative overabundanc

91 A Roux-en-Y gastric bypass is the procedure of choice when

92 ic procedures performed include laparoscopic Roux-en-Y gastric bypass, laparoscopic adjustable gastri

93 laparoscopic Roux-en-Y gastric bypass, open Roux-en-Y gastric bypass, laparoscopic gastric band plac

94 fe (QoL) outcomes compared with laparoscopic Roux-en-Y gastric bypass (LRYGB) are lacking.

95 the baseline intervention using laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve

96 goal length of stay (LOS) after laparoscopic Roux-en-Y gastric bypass (LRYGB) should be 1 day to impr

97 senteric defects closure during laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery reduces the ris

98 en-y gastric bypass (ORYGB) and laparoscopic roux-en-y gastric bypass (LRYGB) were common pre-NCD (56

99 id-term results comparable with laparoscopic roux-en-y gastric bypass (LRYGB) with an improved safety

100 the current standard procedure, laparoscopic Roux-en-Y gastric bypass (LRYGB).

101 c sleeve gastrectomy (LSG) with laparoscopic Roux-en-Y-gastric bypass (LRYGB) are limited.

102 recruited to the study, of whom 81 underwent Roux-en-Y gastric bypass (mean age 16.5 years [SD 1.2],

103 vian Obesity Surgery Registry, 509 patients (Roux-en-Y gastric bypass n=465; sleeve gastrectomy n=44)

104 vian Obesity Surgery Registry, 509 patients (Roux-en-Y gastric bypass n=465; sleeve gastrectomy n=44)

105 Roux-en-Y gastric bypass (n = 161), sleeve gastrectomy (

106 ication plus best medical care (n=96 [33%]), Roux-en-Y gastric bypass (n=96 [33%]), or sleeve gastrec

107 ow-up of 6 years (range: 5-9) after surgery (Roux-en-Y gastric bypass, n = 162; gastric banding, n =

108 orbid obesity and who underwent laparoscopic Roux-en-Y gastric bypass, open Roux-en-Y gastric bypass,

109 Adults having had a laparoscopic Roux-en-Y gastric bypass or a laparoscopic vertical slee

110 ceive either medical treatment or surgery by Roux-en-Y gastric bypass or biliopancreatic diversion.

111 Participants underwent laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrect

112 al therapy alone versus medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy in 150 ob

113 of consecutive patients scheduled to undergo Roux-en-Y gastric bypass or sleeve gastrectomy in three

114 5 or higher who underwent bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) or enrol

115 rapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

116 e-2 diabetes mellitus in patients undergoing Roux-en-Y Gastric Bypass or sleeve gastrectomy.

117 Laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy.

118 rapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

119 dence of symptomatic gallstone disease after Roux-en-Y gastric bypass or sleeve gastrectomy.

120 trial, we enrolled adults who had undergone Roux-en-Y gastric bypass or vertical sleeve gastrectomy

121 festyle modification plus best medical care, Roux-en-Y gastric bypass, or sleeve gastrectomy.

122 Open roux-en-y gastric bypass (ORYGB) and laparoscopic roux-e

123 Patients were randomized to Roux-en-Y gastric bypass plus medical therapy or medical

124 in 3 groups: PBH (n = 13), asymptomatic post-Roux-en-Y gastric bypass (post-RYGB) (n = 10), and nonsu

125 % CI, 1.04-1.15]; P = .01), and undergoing a Roux-en-Y gastric bypass procedure (AOR, 2.07 [95% CI, 1

126 e of 120 patients who underwent laparoscopic Roux-en-Y gastric bypass procedure, in which comprehensi

127 ower interpersonal support) and undergoing a Roux-en-Y gastric bypass procedure.

128 primary, laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass procedures between 2017 and 201

129 The Roux-en-Y gastric bypass produced greater weight loss, H

130 ies (ie, laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass) ranges from 25% to 30% at 12 m

131 Roux-en-Y Gastric Bypass remains an excellent and durabl

132 Laparoscopic Roux-en-Y gastric bypass resulted in greater weight loss

133 Roux-en-Y gastric bypass reversed all of these DIO-induc

134 edures [i.e., a sleeve gastrectomy, proximal Roux-en Y gastric bypass (RYGB), and distal RYGB].

135 from approximately 1000 patients undergoing Roux-en-Y gastric bypass (RYGB) and clinical traits asso

136 Laparoscopic Roux-en-Y gastric bypass (RYGB) and laparoscopic adjusta

137 Roux-en-Y gastric bypass (RYGB) and laparoscopic adjusta

138 to compare the use and short-term outcome of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (

139 Metabolic and bariatric surgery, including Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (

140 Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (

141 ociated with bariatric surgery consisting of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy a

142 nces and taste-induced brain responses after Roux-en-Y gastric bypass (RYGB) and vertical sleeve gast

143 Roux-en-Y gastric bypass (RYGB) and vertical sleeve gast

144 >=35 kg/m(2)) is bariatric surgery, namely, Roux-en-Y gastric bypass (RYGB) and vertical sleeve gast

145 Of the many available options, Roux-en-Y gastric bypass (RYGB) and vertical sleeve gast

146 Rapid glycemic improvements following Roux-en-Y gastric bypass (RYGB) are frequently attribute

147 its development and ultimate remission after Roux-en-Y gastric bypass (RYGB) are not fully understood

148 ing laparoscopic sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are scarce.

149 Sleeve gastrectomy (SG) and Roux-en-Y Gastric Bypass (RYGB) are the two procedures u

150 The antidiabetes effects of Roux-en-Y gastric bypass (RYGB) are well-known, but the

151 pic sleeve gastrectomy (SG) and laparoscopic Roux-en-Y gastric bypass (RYGB) are widely used bariatri

152 al effectiveness and long-term durability of Roux-en-Y Gastric Bypass (RYGB) at an accredited center.

153 The resolution of type 2 diabetes after Roux-en-Y gastric bypass (RYGB) attests to the important

154 proved postprandial beta-cell function after Roux-en-Y gastric bypass (RYGB) but is less studied afte

155 After Roux-en-Y gastric bypass (RYGB) chronic abdominal pain i

156 Subjects were assigned to Roux-en-Y gastric bypass (RYGB) combined with medical th

157 e, clinical cohort of veterans who underwent Roux-en-Y gastric bypass (RYGB) compared with nonsurgica

158 scular-related and all-cause mortality after Roux-en-Y gastric bypass (RYGB) for obesity compared wit

159 urgery, including sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) from 2008 to 2020.

160 lean and obese controls, patients following Roux-en-Y gastric bypass (RYGB) had increased postprandi

161 Improvement in type 2 diabetes after Roux-en-Y gastric bypass (RYGB) has been attributed part

162 Revisional laparoscopic surgery after Roux-en-Y gastric bypass (RYGB) has been linked to subst

163 -1) to postprandial glucose metabolism after Roux-en-Y gastric bypass (RYGB) has been the subject of

164 Roux-en-Y gastric bypass (RYGB) improves glucose homeost

165 BACKGROUND & AIMS: Roux-en-Y gastric bypass (RYGB) improves glucose homeost

166 Roux-en-Y gastric bypass (RYGB) improves glycemic contro

167 pared these to the early and late effects of Roux-en-Y gastric bypass (RYGB) in 22 patients with T2D

168 re we developed the first published model of Roux-en-Y gastric bypass (RYGB) in female rats.

169 y similar metabolic and satiating effects to Roux-en-Y gastric bypass (RYGB) in rodent obesity models

170 n 352 patients (mean BMI 45.8); 6 studies of Roux-en-Y gastric bypass (RYGB) included 131 patients (m

171 Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) induce substantial weigh

172 Roux-en-Y gastric bypass (RYGB) involves exclusion of ma

173 Roux-en-Y gastric bypass (RYGB) is an effective treatmen

174 Weight regain or insufficient loss after Roux-en-Y gastric bypass (RYGB) is common.

175 BACKGROUND AND AIMS: Hyperoxaluria after Roux-en-Y gastric bypass (RYGB) is generally attributed

176 Roux-en-Y gastric bypass (RYGB) is highly effective in r

177 Roux-en-Y gastric bypass (RYGB) is the most common baria

178 The effect of a Roux-en-Y gastric bypass (RYGB) on body weight has been

179 providing further evidence for the impact of Roux-en-Y gastric bypass (RYGB) on both glycemic control

180 influence of sleeve gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB) on liver function in bar

181 atrophin in pregnant women with a history of Roux-En-Y gastric bypass (RYGB) operation with a high ri

182 rded Current Procedural Terminology code for Roux-en-Y gastric bypass (RYGB) or adjustable gastric ba

183 Three years after Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustab

184 ents in pain and physical function following Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustab

185 ants with type 2 diabetes were randomized to Roux-en-Y gastric bypass (RYGB) or nonsurgical diabetes/

186 type 2 diabetes mellitus were randomized to Roux-en-Y gastric bypass (RYGB) or to hypocaloric diet (

187 Bariatric procedures, such as Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastr

188 Roux-en-Y gastric bypass (RYGB) produces substantial bod

189 Roux-en-Y gastric bypass (RYGB) reduces body weight and

190 Roux-en-Y gastric bypass (RYGB) remains one of the most

191 Roux-en-Y gastric bypass (RYGB) restricts food intake, a

192 r time in drug use among patients undergoing Roux-en-Y gastric bypass (RYGB) surgery and a matched po

193 Both Roux-en-Y gastric bypass (RYGB) surgery and exercise can

194 Existing mouse models of Roux-en-Y gastric bypass (RYGB) surgery are not comparab

195 e mechanisms of metabolic improvements after Roux-en-Y gastric bypass (RYGB) surgery are not entirely

196 studies on the prevalence of symptoms after Roux-en-Y gastric bypass (RYGB) surgery are sparse.

197 Roux-en-Y gastric bypass (RYGB) surgery causes profound

198 The amount of weight loss attained after Roux-en-Y gastric bypass (RYGB) surgery follows a wide a

199 morbid disease and weight loss 5 years after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesi

200 ins on type 2 diabetes (T2D) remission after Roux-en-Y gastric bypass (RYGB) surgery for patients tak

201 bjects increased their improvement following Roux-en-Y gastric bypass (RYGB) surgery in hepatic and s

202 While Roux-en-Y gastric bypass (RYGB) surgery in obese individ

203 ic malabsorptive surgical techniques such as Roux-en-Y Gastric Bypass (RYGB) surgery in the managemen

204 Roux-en-Y gastric bypass (RYGB) surgery is an effective

205 pharmacodynamic (PD) study to assess whether Roux-en-Y gastric bypass (RYGB) surgery is associated wi

206 Roux-en-Y gastric bypass (RYGB) surgery is one of the mo

207 oscopic adjustable gastric banding (LAGB) or Roux-en-Y gastric bypass (RYGB) surgery on the metabolic

208 ts with type 2 diabetes mellitus who undergo Roux-en-Y gastric bypass (RYGB) surgery or standard medi

209 Roux-en-Y gastric bypass (RYGB) surgery results in exagg

210 o acids (BCAAs) after weight loss induced by Roux-en-Y gastric bypass (RYGB) surgery than after calor

211 l treatment of type 2 diabetes after primary Roux-en-Y gastric bypass (RYGB) surgery, in patients wit

212 uptake and metabolism are upregulated after Roux-en-Y gastric bypass (RYGB) surgery, which contribut

213 se disorders can be improved or prevented by Roux-en-Y gastric bypass (RYGB) surgery.

214 or risk factors associated with mortality in Roux-en-Y gastric bypass (RYGB) surgery.

215 re reversed following weight loss induced by Roux-en-Y gastric bypass (RYGB) surgery.

216 n response to an oral glucose stimulus after Roux-en-Y gastric bypass (RYGB) surgery.

217 s durability of the efficacy associated with Roux-en-Y gastric bypass (RYGB) surgery.

218 Roux-en-Y gastric bypass (RYGB) was associated with a hi

219 Sleeve gastrectomy (1) and Roux-en-Y gastric bypass (RYGB) were also recognized as

220 ompare vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) with respect to diabetes

221 after one-anastomosis gastric bypass (OAGB), Roux-en-Y gastric bypass (RYGB), and sleeve gastrectomy

222 oglycemia (PBH) is a serious complication of Roux-en-Y gastric bypass (RYGB), characterized by severe

223 We identified patients who underwent Roux-en-Y gastric bypass (RYGB), cholecystectomy, partia

224 Bariatric surgery procedures, in particular Roux-en-Y gastric bypass (RYGB), have been associated wi

225 Roux-en-Y gastric bypass (RYGB), laparoscopic adjustable

226 cluding gastric banding, sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB), modified RYGB (mRYGB) a

227 d the effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), on the 1-y remission of

228 ity-related medical complications, underwent Roux-en-Y gastric bypass (RYGB), one-anastomosis gastric

229 andomly assigned (1:1:1) to medical therapy, Roux-en-Y gastric bypass (RYGB), or biliopancreatic dive

230 cyl-ghrelin due to fasting, eating, obesity, Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrec

231 Roux-en-Y gastric bypass (RYGB)-induced glycemic improve

232 s of apolipoprotein A-IV (apoA-IV) rise with Roux-en-Y gastric bypass (RYGB).

233 s and the systemic metabolomic profile after Roux-en-Y gastric bypass (RYGB).

234 for weight loss and diabetes remission after Roux-en-Y gastric bypass (RYGB).

235 hanisms for improved glucose tolerance after Roux-en-Y gastric bypass (RYGB).

236 atic diversion with duodenal switch (DS) and Roux-en-Y Gastric Bypass (RYGB).

237 fying alcohol-related problems in women post-Roux-en-Y gastric bypass (RYGB).

238 lowing vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB).

239 ght loss and HbA1c improvement compared with Roux-en-Y gastric bypass (RYGB).

240 Postprandial hypoglycemia is a risk after Roux-en-Y gastric bypass (RYGB).

241 predictive markers for T2DM remission after Roux-en-Y gastric bypass (RYGB).

242 diction score for internal hernia (IH) after Roux-en-Y gastric bypass (RYGB).

243 c hypoglycemia (PHH) is often reported after Roux-en-Y gastric bypass (RYGB).

244 ical factors and long-term weight loss after Roux-en-Y gastric bypass (RYGB).

245 gastroplasty/banding (GP/B): all revised to Roux-en-Y gastric bypass (RYGB); and 66 gastric bypass:

246 Patients underwent Roux-en-Y gastric bypass (RYGB, n = 275) or laparoscopic

247 ic neurotransmission would be enhanced after Roux-en-Y-Gastric Bypass (RYGB) and Vertical Sleeve Gast

248 rvention for 2 years or surgical treatments (Roux-en-Y gastric bypass [RYGB] or laparoscopic adjustab

249 zation sequence, stratified by surgery type (Roux-en-Y gastric bypass [RYGB] or sleeve gastrectomy [S

250 enhance the beneficial effect of bariatric (Roux-en-Y gastric bypass [RYGB]) surgery on insulin resi

251 Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy

252 emarkable remission of type 2 diabetes after Roux-en-Y gastric bypass (RYGBP) are still puzzling.

253 Roux-en-Y gastric bypass (RYGBP) is known to reduce zinc

254 y the effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGBP) on heme- and nonheme-ir

255 Long-term health maintenance after Roux-en-Y gastric bypass should focus on adherence to di

256 Bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy) vs nonsurg

257 Bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy, and other

258 e following 3 bariatric surgical procedures: Roux-en-Y gastric bypass, sleeve gastrectomy, or adjusta

259 re eligible for bariatric surgery, including Roux-en-Y gastric bypass, sleeve gastrectomy, or adjusta

260 atified by type of surgery (gastric banding, Roux-en-Y gastric bypass, sleeve gastrectomy, or other/u

261 cts of vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass surgeries for obesity.

262 festyle and medical management plus standard Roux-en-Y gastric bypass surgery (gastric bypass).

263 Participants received either laparoscopic Roux-en-Y gastric bypass surgery (n = 100) or laparoscop

264 with type 2 diabetes mellitus shortly after Roux-en-Y gastric bypass surgery (RYGB) and before there

265 Roux-en-Y gastric bypass surgery (RYGB) results in remis

266 nd effective treatment for morbid obesity is Roux-en-Y gastric bypass surgery (RYGB), which results i

267 n = 10) and without T2D (n = 9) subjected to Roux-en-Y gastric bypass surgery (RYGB).

268 Roux-en-Y gastric bypass surgery (RYGBP), the most commo

269 s with type 2 diabetes mellitus-1 managed by Roux-en-Y gastric bypass surgery and a comparable group

270 (VAT) in morbidly obese subjects undergoing Roux-en-Y gastric bypass surgery compared to lean contro

271 lated the benefits and harms of laparoscopic Roux-en-Y gastric bypass surgery in patients defined by

272 articular, patients who undergo laparoscopic Roux-en-Y gastric bypass surgery may be at increased ris

273 ion, participants who underwent laparoscopic Roux-en-Y gastric bypass surgery reported a significant

274 INTERPRETATION: Roux-en-Y gastric bypass surgery resulted in substantial

275 monstrated that after 10 years of follow-up, Roux-en-Y gastric bypass surgery, compared with nonsurgi

276 associated with diabetes remission following Roux-en-Y gastric bypass surgery, suggesting new therape

277 s treated with SRIs frequently relapse after Roux-en-Y gastric bypass surgery, the authors sought to

278 ntensive medical management intervention and Roux-en-Y gastric bypass surgery.

279 dogenous hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass surgery.

280 obese individuals before and 9 months after Roux-en-Y gastric bypass surgery.

281 ss in individuals with and without PBH after Roux-en-Y gastric bypass surgery.

282 .5 (mean = 5.6) years) weight loss following Roux-en-Y gastric bypass surgery.

283 roups: 418 patients who sought and underwent Roux-en-Y gastric bypass (surgery group), 417 patients w

284 ts of an observational, prospective study of Roux-en-Y gastric bypass that was conducted in the Unite

285 Roux-en-Y gastric bypass, the most widely performed proc

286 rol and treatment risks 2 years after adding Roux-en-Y gastric bypass to intensive lifestyle and medi

287 Laparoscopic Roux-en-Y gastric bypass, vertical sleeve gastrectomy, a

288 mum follow-up for LAGB was 54.2% EWL and for Roux-en-Y gastric bypass was 54.0% EWL.

289 Roux-en-Y gastric bypass was associated with relatively

290 Laparoscopic Roux-en-Y gastric bypass was consistently among the top

291 A Roux-en-Y gastric bypass was performed in morbidly obese

292 Roux-en-Y gastric bypass was the most common procedure.

293 associated with greater weight regain after Roux-en-Y gastric bypass, which inform patient care to i

294 y of patients who had undergone laparoscopic Roux-en-Y gastric bypass with surgically confirmed IH (n

295 tcomes of adolescent surgical patients after Roux-en-Y gastric bypass with those of conservatively tr